NasdaqCM - Nasdaq Real Time Price USD

Nuwellis, Inc. (NUWE)

0.9888

+0.0309

+(3.23%)

At close: May 9 at 4:00:00 PM EDT

1.0100

+0.02

+(2.14%)

After hours: May 9 at 7:39:44 PM EDT

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

The Company has 47 Pediatric Centers utilizing AquadexMINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have ado

GlobeNewswire 2 days ago

NUWE
+3.23%

NUWEW
Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

WHOWHATWHEREWHENWHYNuwellis, Inc.Issuance of U.S. Patent No. 12,280,007.United States Patent and Trademark OfficeApril 22, 2025To protect a novel self-emptying fluid bag design that improves nursing workflow while maintaining system accuracy. MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent

GlobeNewswire 16 days ago

NUWE
+3.23%

NUWEW
Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis

GlobeNewswire 18 days ago

NUWE
+3.23%

NUWEW
Nuwellis Inc (NUWE) Q4 2024 Earnings Call Highlights: Navigating Revenue Challenges with ...

Nuwellis Inc (NUWE) reports a mixed quarter with a decline in overall revenue but significant growth in critical care and consumables utilization, alongside strategic initiatives for future expansion.

GuruFocus.com 19 days ago

NUWE
+3.23%

NUWEW
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltratio

GlobeNewswire last month

NUWE
+3.23%

NUWEW
Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

John Erb, Current Chair of the Board, Appointed Interim President and CEOMINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of

GlobeNewswire 2 months ago

NUWE
+3.23%

NUWEW
JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

WHOWHATWHEREWHENWHYNuwellis, Inc., and Dr. Sean P. Pinney and Dr. Maria V. DeVitaUpdated analysis of the AVOID-HF study data shows that Aquadex® SmartFlow ultrafiltration therapy led to a 60% reduction in heart failure events compared to standard diuretic therapy.Journal of the American College of CardiologyFindings were recently updated and analyzed as of 2/19/25These promising results support further research into ultrafiltration's role in heart failure management and highlight its potential t

GlobeNewswire 2 months ago

NUWE
+3.23%

NUWEW
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page

GlobeNewswire 2 months ago

NUWE
+3.23%

NUWEW
Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, is pleased to announce its newest pediatric hospital customer, a nationally ranked hospital in Utah. The hospital, Nuwellis’ 44th pediatric account, will be utilizing the Aquadex SmartFlow® system to treat children suffering from fluid overload caused by kidney and heart disease. Since 2020 when the FDA granted clearance, Nuwe

GlobeNewswire 3 months ago

NUWE
+3.23%

NUWEW
Nuwellis Regains Compliance with Nasdaq Listing Requirements

MINNEAPOLIS, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (the “Company” or “Nuwellis”) today announced that the Company received formal written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The

GlobeNewswire 4 months ago

NUWE
+3.23%

NUWEW
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights: Received a 297% CMS reimbursement increase to $1,639 for Aquadex facility fee, effective January 1, 2025.Revenue of $2.4 million.Pediatrics revenue growth of 28% compared to the prior year quarter.Gross margin of 70%, compared to 57

GlobeNewswire 5 months ago

NUWE
+3.23%

NUWEW
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company’s common stock at their c

GlobeNewswire 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis Stock Soars 121% on Major Increase in Reimbursement for Aquadex System

Nuwellis' Aquadex System Receives Significant Reimbursement Increase

GuruFocus.com 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reim

GlobeNewswire 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis Announces Preliminary Results for Third Quarter of 2024

MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. Based on preliminary, unaudited results, management expects the Company to report

GlobeNewswire 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family Children’s Hospital in Iowa City, Iowa, has adopted the Aquadex SmartFlow® system to treat pediatric patients suffering from fluid overload due to heart and kidney disease. The Stead Family Children’s Hospital will use the Aquadex SmartFlow system to p

GlobeNewswire 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis we

GlobeNewswire 6 months ago

NUWE
+3.23%

NUWEW
Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners’ third annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024. Investor presentations and other materials used at the conference will be available on the investor relations se

GlobeNewswire 7 months ago

NUWE
+3.23%

NUWEW
New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

MINNEAPOLIS, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce the publication of a new study in Current Problems in Cardiology demonstrating the effectiveness of Aquadex® ultrafiltration therapy in reducing 60 day hospital readmission rates for patients with acutely decompensated heart failure (ADHF) who are otherwise resistant to diuretic treatment. The study,

GlobeNewswire 8 months ago

NUWE
+3.23%

NUWEW
Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 496,901 shares of the Company’s common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market un

GlobeNewswire 8 months ago

NUWE
+3.23%

NUWEW

Performance Overview

Return	NUWE	S&P 500 (^GSPC)
YTD	-10.92%	-3.77%
1-Year	-89.54%	+8.55%
3-Year	-99.96%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nuwellis, Inc. (NUWE)

Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

Nuwellis Inc (NUWE) Q4 2024 Earnings Call Highlights: Navigating Revenue Challenges with ...

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Nuwellis Adds Nationally Ranked Utah Hospital as New Pediatric Customer for Aquadex SmartFlow® Therapy

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Nuwellis Stock Soars 121% on Major Increase in Reimbursement for Aquadex System

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

New Study Published in Current Problems in Cardiology Highlights Statistically Significant Reduction in Heart Failure Readmissions at 60 days when using the Aquadex Ultrafiltration Therapy

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Performance Overview